Huvepharma, a leading global provider of animal health and nutrition solutions, and Qilu Tsingta, a Chinese specialist in coccidiosis vaccine production, today announced a strategic partnership for the development and commercialization of innovative coccidiosis vaccines.
A strategic alliance for animal health
This collaboration will enable Huvepharma to expand its coccidiosis control portfolio by leveraging Qilu Tsingta's expertise in vaccine production and its strong presence in the Chinese market. Qilu Tsingta will gain access to Huvepharma's R&D, technical, and marketing resources, as well as a complementary product portfolio, to better serve key livestock accounts in China.
Driving innovation for the livestock industry
Mr. Johnny Chiang, Managing Director Huvepharma China, stated: "This partnership marks a significant step in our growth strategy and presence in China. Qilu Tsingta's expertise perfectly complements our existing coccidiosis solutions. Together, we will enhance vaccine quality, deliver tailored services to key Chinese customers, and develop new tools to address the evolving challenges of the livestock industry."
Mr. Xuezhi Zhang, Managing Director Qilu Tsingta added: "Our partnership with Huvepharma will strengthen our service offerings and product range for key clients. It will also open new avenues for R&D and allow us to leverage Huvepharma's global network and expertise in poultry production, to better serve global customers."
About Huvepharma
Huvepharma is a fast-growing global pharmaceutical and nutrition company focused on the development, manufacturing, and marketing of human and animal health and nutrition products. Well-known for its expertise in fermentation and production, Huvepharma has established itself as one of the top ten veterinary pharmaceutical companies worldwide. Headquartered in Sofia, Bulgaria, Huvepharma serves customers all over the world, operating through its manufacturing subsidiary, Biovet, based in Peshtera, Bulgaria, with independent production units in multiple locations. The company's modern fermentation, purification, and R&D facilities enable the production of major molecules and high-quality finished products. With an extensive global commercial network of sales offices, subsidiaries and local representatives in most countries, there is always a member of the Huvepharma team ready to provide expert support.
About Qilu Tsingta
Qilu Tsingta was founded in 2014, and is a national high-tech enterprise specializing in the research and development, production, and sales of live coccidiosis vaccines for chickens. The unique preservation technology of master strains ensures the stability of product efficacy. The strong R&D capabilities have not only enabled its live coccidiosis vaccine for chickens to have strong immune protection, mild intestinal side effects, and improved overall feed conversion ratio, but have also gained high recognition from many large-scale poultry producers in China. After years of market validation and development, Qilu Tsingta has become one of the major manufacturers of coccidiosis vaccines in China and is further committed to becoming a global coccidiosis vaccine innovator.
Huvepharma was advised throughout the transaction by Shiyao Investment Ltd.
About Shiyao Investment Ltd
Shiyao Investment Ltd provides strategic advisory and investment banking services with a strict focus on the complete supply chain of agribusiness, related life sciences (including animal health and animal nutrition), food and beverage production and distribution in Asia, in particular Greater China and Japan.
